Skip to main content

Table 2 Clinical trial registrations on allogeneic CAR-T cell infusion after allo-HSCT in B cell malignancies

From: Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies

Center

Disease

Status of disease

Activation motif of CAR

Drugs

Numbers of CAR-T cells

Phase

Status

Registered ID

National Cancer Institute (NCI), American

B cell cancer

Either did not respond to or recurred after allogeneic transplantation

Not shown

Cy 180 mg/m2 for 3 days and pentostatin 4 mg/m2 for 1 day

Dose escalation

I

Suspended

NCT01087294

University of Pennsylvania, American

CD19+ ALL

Relapse after allogeneic transplantation

4-1BB

Not shown

Not shown (split infusion over 3 days)

I

Completed

NCT01551043

Department of Hematology, Xinqiao Hospital, China

B-ALL

Molecular relapse after allogeneic transplantation

Not shown

No

1 × 106/kg

II

Recruiting

ChiCTR-OOC-16008447

  1. Note: The trials are registered at ClinicalTrials.gov and http://www.chictr.org.cn/index.aspx. Search was performed on December 18, 2016.
  2. CAR-T chimeric antigen receptors redirected T cells, allo-HSCT allogeneic stem cell transplantation, Cy cyclophosphamide, B-ALL B cell acute lymphoblastic leukemia